Zobrazeno 1 - 10
of 25
pro vyhledávání: '"G. Frank Liu"'
Publikováno v:
BMC Medical Research Methodology, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background The data from immuno-oncology (IO) therapy trials often show delayed effects, cure rate, crossing hazards, or some mixture of these phenomena. Thus, the proportional hazards (PH) assumption is often violated such that the commonly
Externí odkaz:
https://doaj.org/article/d71dc0ae22024f8a90d38c2728d0980d
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 10, Pp 2357-2363 (2017)
Although clinical trials of the pentavalent rotavirus vaccine (RotaTeq®, RV5) have demonstrated efficacy against RV gastroenteritis (RGE) in low and high-income settings, a clear correlate of protection or a measure of immune response that could pre
Externí odkaz:
https://doaj.org/article/1471cc6bced24320a70bf638d415e5f7
Publikováno v:
Statistics in Biopharmaceutical Research. 14:444-455
The medical community has been keen on developing disease-modifying (DM) products that can delay the underlying pathological or pathophysiological disease processes when treating chronic progressive diseases such as Alzheimer’s disease, Parkinson
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2407bbc19db13b27a0f8a8686eb23095
https://doi.org/10.1080/19466315.2021.2008483
https://doi.org/10.1080/19466315.2021.2008483
Publikováno v:
Statistics in Biopharmaceutical Research. 14:626-635
The International Council for Harmonisation (ICH) recently published an E9(R1) addendum that requires the estimand associated with the study objective in clinical trials to be clearly defined. One of the challenges in defining an estimand is the esti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43481b3c36e575cc3a12867a9e54ada4
https://doi.org/10.1080/19466315.2021.1924256
https://doi.org/10.1080/19466315.2021.1924256
Publikováno v:
BMC Medical Research Methodology
BMC Medical Research Methodology, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Medical Research Methodology, Vol 20, Iss 1, Pp 1-10 (2020)
Background The data from immuno-oncology (IO) therapy trials often show delayed effects, cure rate, crossing hazards, or some mixture of these phenomena. Thus, the proportional hazards (PH) assumption is often violated such that the commonly used log
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb22e8120b105bbcc5833552f7ac1fa2
https://doi.org/10.21203/rs.3.rs-24267/v3
https://doi.org/10.21203/rs.3.rs-24267/v3
Publikováno v:
Human Vaccines & Immunotherapeutics. 13:2357-2363
Although clinical trials of the pentavalent rotavirus vaccine (RotaTeq®, RV5) have demonstrated efficacy against RV gastroenteritis (RGE) in low and high-income settings, a clear correlate of protection or a measure of immune response that could pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f597514e2f801dd35f3b758da6111f40
https://doi.org/10.1080/21645515.2017.1356522
https://doi.org/10.1080/21645515.2017.1356522
Autor:
G. Frank Liu, Lei Pang
Publikováno v:
Statistics in Biopharmaceutical Research. 9:186-194
Sensitivity analyses using multiple imputation (MI) provide a flexible approach to assess the impact of missing data on clinical trial results. An approach that imputes missing data in the test drug group using a model built from the control group ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beea49a2496af6a39cb08011fa98a1ec
https://doi.org/10.1080/19466315.2016.1256830
https://doi.org/10.1080/19466315.2016.1256830
Autor:
Eddy Ziani, G. Frank Liu, Jon E. Stek, Florence Boisnard, Timo Vesikari, Marco F. Pagnoni, Katleen Poschet, Sheryl A. Flores, Andrew W. Lee, Stéphane Thomas, Thomas Becker, Jin Xu, André Vertruyen
Publikováno v:
Pediatric Infectious Disease Journal. 36:209-215
Combination vaccines simplify vaccination visits and improve coverage and timeliness. Diphtheria-tetanus toxoids-acellular pertussis 5, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b (DTaP5-HB-IPV-Hib) is a new investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68209c03854b0dc9038c8fea3ad95635
https://doi.org/10.1097/inf.0000000000001406
https://doi.org/10.1097/inf.0000000000001406
Historical information can be used to improve the efficiency of the development process for a medical product (drug, vaccine, or device) and to provide an approach to address indirectly clinically important questions that cannot be addressed directly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ab0d8668b7c1820b91d3608403dc14f
https://doi.org/10.1201/9781315099798-2
https://doi.org/10.1201/9781315099798-2
Missing data is common in clinical trials but is often inadequately handled which could have an impact on estimation and testing of treatment effects. Based on the National Research Council (NRC) recommendations, regulatory agencies are requesting mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40cc1dc0ebbbc994e198a22a286f5846
https://doi.org/10.1201/9781315099798-10
https://doi.org/10.1201/9781315099798-10